No legal services. No KK, GK, or US entity formation. No L-1, E-2, or visa work. No US tax structuring, transfer-pricing analysis, or Japan-US double-taxation treaty review. No US banking introductions. No fiduciary services. No regulatory licensing, FDA submissions, PMDA conformity, or US securities work. No IP filing or patent prosecution. No contract drafting. No US recruiting or executive search. No M&A advisory.
These belong with Japanese counsel who specialise in US entry, with US counsel on the American side, and with regulatory consultants who handle FDA and clinical pathways. The firm works inside the parameters they set. When a marketing decision carries legal, tax, or regulatory implications, the firm flags it and defers before execution.